SAN FRANCISCO (GenomeWeb) – Natera said it is on track for an end of the year or early 2019 launch of a clinical version of its circulating tumor DNA assay Signatera and that it planned to eventually submit it to both the US Food and Drug Administration and the Centers for Medicare and Medicaid Services.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.